A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
Phase 3
200
about 2.8 years
18–63
81 sites in AL, AR, AZ +24
About this study
This trial is testing whether upadacitinib, at different doses, is effective for adults with moderate-to-severe atopic dermatitis who haven't responded well to dupilumab. It involves two periods: in the first period, participants receive either upadacitinib 15mg or dupilumab 300mg; if they respond well to upadacitinib 15mg, their dose may be increased to upadacitinib 30mg. In the second period, participants continue on their assigned treatment or are reassigned based on their response to eczema.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Dupilumab 300mg Dose
- 2.Take Upadacitinib 15mg Dose
- 3.Take Upadacitinib 30mg Dose
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
oral (Oral Solution)
Secondary: Participants who simultaneous achieve at least a 90% reduction in Eczema Area and Severity Index from Baseline (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1), Percentage of participants achieving worst pruritus numerical rating scale (WP-NRS) 0/1, Percentage of participants who achieve a Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1)
Dermatology